Table 2.
Clinical response
| Sorafenib (n = 65) | Placebo (n = 33) | |
|---|---|---|
| Best response on study, n (%) | ||
| Overall response rate (CR/CRi) | 57 (88) | 31 (94) |
| CR | 51 (78) | 23 (70) |
| CRi | 6 (9) | 8 (24) |
| PR | 4 (6) | 0 |
| No response | 3 (5) | 1 (3) |
| Response not available | 1 (2) | 1 (3) |
| Response rates within 60 days, n (%) | ||
| Overall response rate (CR/CRi) | 55 (82) | 31 (94) |
| CR | 41 (63) | 21 (64) |
| CRi | 14 (22) | 10 (30) |
| PR | 6 (9) | 0 |
| No response | 3 (5) | 1 (3) |
| Response not available | 1 (2) | 1 (3) |
CR, complete remission; CRi, CR with incomplete hematologic recovery; PR, partial remission.